Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for teens with rare tumors: targeted radiation drug under study

NCT ID NCT04711135

First seen Feb 13, 2026 · Last updated May 23, 2026 · Updated 13 times

Summary

This study looks at how safe a radioactive drug called Lutathera is for teenagers aged 12 to 18 with certain rare tumors of the gut or adrenal glands. The goal is to measure radiation doses to organs and track side effects. Lutathera is not a cure; it aims to control tumor growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Centre Léon Berard

    Lyon, France

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Cincinnati Children's Hospital

    Cincinnati, Ohio, 45229-3039, United States

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Maria Sklodowska-Curie National Research Institute of Oncology

    Gliwice, Poland

  • University College Hospital of London

    London, United Kingdom

  • University of Kentucky

    Lexington, Kentucky, 40536, United States

Conditions

Explore the condition pages connected to this study.